| Company Name: |
Biosynth Ltd |
| Tel: |
18886812933 |
| Email: |
sales@biosynth.com |
| Company Name: |
Abmart Inc |
| Tel: |
4006-123-828 13162017139 |
| Email: |
market@ab-mart.com |
|
| | NUB1 Antibody Chemical Properties |
| | NUB1 Antibody Usage And Synthesis |
| Source | Rabbit | | Reactivity | Human;Mouse;Rat;Monkey | | Background | Both the NEDD8 ultimate buster 1 and the related NUB1L isoform are interferon-inducible adaptor proteins that negatively regulate ubiquitin-like protein NEDD8. NUB1 protein contains an amino terminal ubiquitin-like domain and multiple carboxy terminal ubiquitin-associated domains. The NUB1L isoform is generated by alternative splicing and contains an extra UBA domain relative to NUB1. Research studies indicate that NUB1 and NUB1L non-covalently bind NEDD8 and facilitate delivery of both NEDD8 monomers and NEDD8 conjugates to the proteasome for degradation. In addition, NUB1L binds and enhances the proteasomal degradation of the FAT10 ubiquitin-like protein. Additional research shows that NUB1 negatively regulates cell proliferation, likely due to inhibition of NEDD8 conjugation to SCF ubiquitin ligases, which leads to inhibition of p27 and cyclin E ubiquitination. NUB1 has been identified as a putative therapeutic target in Huntington's disease as NUB1 promotes a decrease in levels of mutant HTT protein. | | References | [1] Kamitani, T. et al. (2001) J Biol Chem 276, 46655-60.
[2] Tanaka, T. et al. (2003) J Biol Chem 278, 32905-13.
[3] Kito, K. et al. (2001) J Biol Chem 276, 20603-9.
[4] Tanji, K. et al. (2005) Biochem Biophys Res Commun 337, 116-20.
[5] Liu, S. et al. (2013) J Biol Chem 288, 31339-49.
[6] Hipp, M.S. et al. (2004) J Biol Chem 279, 16503-10.
[7] Hosono, T. et al. (2010) Br J Cancer 102, 873-82.
[8] Lu, B. et al. (2013) Nat Neurosci 16, 562-70. |
| | NUB1 Antibody Preparation Products And Raw materials |
|